70
Participants
Start Date
January 10, 2014
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Spironolactone
Initial dose, 25 mg (pink capsule) orally, daily. If well tolerated at 7-9 wks then increased to 50 mg (brown capsule) daily.
Placebo
Initial dose, pink sugar capsule, daily. If well tolerated at 7-9 wks then changed to brown sugar capsule, daily.
RECRUITING
National Institutes of Health Clinical Center, Bethesda
Collaborators (1)
National Heart, Lung, and Blood Institute (NHLBI)
NIH
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
University of Pennsylvania
OTHER
University of Maryland, Baltimore
OTHER
Medstar Health Research Institute
OTHER
New England Medical Center, Tufts University School of Medicine
UNKNOWN
National Institutes of Health Clinical Center (CC)
NIH